Roche rings Bicycle bell again, grabbing another cancer target
pharmaphorum
JULY 13, 2022
Bicycle said that none of the compounds in its in-house oncology pipeline, including its immuno-oncology candidates, are included in the Genentech collaboration. Genentech has been looking at the platform since 2020 under the terms of a deal worth up to $1.7
Let's personalize your content